Reset

Advanced Filters
03:30pm - 05:00pm EDT - March 18, 2021

Thursday


Objectives:
  • Discuss the benefits and challenges associated with collecting and utilizing patient-reported outcomes.
  • Apply best practices for incorporating patient-reported outcomes into routine clinical care.
Thursday
03:30pm - 04:15pm EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Select optimal adjuvant treatment strategies for patients with HER2-positive early-stage breast cancer based on risk of recurrence.
  • Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer.
  • Plan effective therapy for patients with HER2-positive metastatic breast cancer and central nervous system (CNS) metastases.
Thursday


Objectives:
  • Identify the most common hereditary RCC syndromes and their clinical features.
  • Discuss screening and surveillance strategies for patients with a confirmed hereditary RCC syndrome.
  • Review treatment options for patients with a confirmed hereditary RCC syndrome.
Thursday
03:30pm - 04:00pm EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Recognize the importance of assessing mutational status in GISTs and its treatment and prognostic implications.
  • Review the existing treatment modalities for unresectable and metastatic GISTs and the high rate of drug resistance.
  • Discuss the impact of avapritinib and ripretinib, the two new FDA-approved agents, on the treatment of advanced GISTs.
Thursday


Objectives:
  • Discuss the role of NGS-based techniques in the management of gastroesophageal cancers.
  • Describe the treatment options for second-line and subsequent therapy for patients with metastatic gastroesophageal cancers.
  • Compare and contrast the current evidence for treating metastatic gastric cancer with targeted therapies, and when appropriate, include in the management of these patients.
Thursday
04:15pm - 05:00pm EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Select optimal neoadjuvant/adjuvant therapy for locally advanced triple negative breast cancer.
  • Recognize key patient factors that influence selection of systemic therapy for metastatic triple negative breast cancer.
  • Optimally manage common toxicities related to new agents used to treat triple negative breast cancer.
11:00am - 12:30pm EDT - March 19, 2021

Friday


Objectives:
  • Identify clinical challenges in managing patients with a variety of cancers.
  • Develop an evidence-based approach for the management of these patients.
Friday


Objectives:
  • Recognize the barriers to fertility preservation in AYAs with cancer, including lack of adequate knowledge among providers.
  • Assess the risks of gonadotoxicity/gonadal insufficiency associated with various anti-neoplastic regimens, as estimated by the standardized risk stratification model proposed by the Oncofertility Consortium.
  • Discuss the various fertility preservation methods and alternatives currently available for female and male AYAs.
Friday
11:00am - 11:45am EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Evaluate novel and emerging treatment strategies for acute myeloid leukemia (AML) and integrate them into the management of appropriate patients.
  • Compare and contrast factors used for posttreatment risk stratification in AML.
  • Summarize supportive care considerations for novel and emerging AML therapies.
Friday


Objectives:
  • Recognize health-related quality of life issues that impact patients with head and neck cancer.
  • Identify strategies for optimal nutrition management in patients with head and neck cancer.
  • Describe the risk of dental complications following radiation therapy treatment to the head and neck and strategies to prevent and address complications, including use of advanced radiation therapy techniques.
Friday


Objectives:
  • Discuss the results of recent and emerging clinical trials of immune checkpoint inhibitors and their potential impact on treatment of urothelial bladder cancer.
  • Review recent updates to the NCCN Guidelines for Bladder Cancer and how they may be incorporated into clinical practice.
  • Describe systemic therapy options for patients with urothelial bladder cancer, along with how patient and disease characteristics can guide therapy choice.
Friday
11:45am - 12:30pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Select optimal therapies for patients with heavily pretreated multiple myeloma (MM) based on individual patient and disease characteristics.
  • Manage toxicities of the newer agents and combination regimens in patients with MM.
  • Review current management strategies of SMM and MM and effectively convey the benefits and risks of clinical trial participation to patients.
03:30pm - 04:15pm EDT - March 19, 2021

Friday
03:30pm - 04:15pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Recognize the various types of uterine sarcomas and mixed epithelial/mesenchymal tumors.
  • Discuss the challenges of differentiating between these types of tumors.
  • Describe how molecular profiling can be used to help diagnose uterine sarcomas and carcinosarcomas, assess prognosis, and guide treatment decisions.
Friday
03:30pm - 04:15pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe the total neoadjuvant therapy approach for treating locally advanced rectal cancer and the results from clinical trials investigating this approach.
  • Discuss emerging treatment options for metastatic colorectal cancer and which patients might benefit from these new therapies based on clinical characteristics and biomarker results.
  • Apply clinical trial data into treatment strategies for locally advanced rectal cancer and metastatic colorectal cancer.
Friday


Objectives:
  • Review the treatment options for patients with relapsed or refractory CLL/SLL.
  • Discuss available evidence on sequencing therapy for patients with relapsed/refractory disease and develop an individualized treatment plan based on prior first-line therapy, disease-specific and patient-specific characteristics.
  • Describe the role of minimal residual disease (MRD) assessment and its implications on the management of patients with CLL/SLL.
Friday
03:30pm - 04:15pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe when systemic therapy may be appropriate for patients with thyroid carcinoma.
  • Identify systemic therapy options for advanced thyroid carcinoma.
  • Recognize side effects that are commonly reported in patients with thyroid carcinoma who are treated with systemic therapy.
04:15pm - 05:00pm EDT - March 19, 2021

Friday
04:15pm - 05:00pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe data from PARP inhibitor trials in patients with newly-diagnosed advanced ovarian cancer, and discuss how it may inform treatment and molecular testing in this setting.
  • Review factors that may impact the extent of clinical benefit from PARP inhibitor therapy.
  • Compare and contrast considerations for selecting recurrence therapy in patients who have progressed/recurred on or after PARPi maintenance.
Friday
04:15pm - 05:00pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Compare and contrast the differences between systemic therapy options available for first-line treatment of hepatobiliary cancers.
  • Describe how molecular profiling can help better inform clinical decision-making.
  • Identify the different options available for the treatment of hepatobiliary cancers based on the genetic abnormality detected.
Friday
04:15pm - 05:00pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe the current treatment approach and the rationale for the development of novel treatment options for relapsed/refractory B-cell lymphomas.
  • Review the efficacy of currently approved as well as investigational CAR T-cell therapies for relapsed or refractory B-cell lymphomas.
  • Evaluate the strategies for the management of unique toxicities associated with CAR T-cell therapies, and integrate CAR T-cell therapy into the overall treatment plan in appropriate patients with relapsed or refractory B-cell lymphomas.
Friday
04:15pm - 05:00pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Compare and contrast therapeutic approaches for treatment of salivary gland tumors.
  • Recognize when systemic therapy may be appropriate for patients with salivary gland tumors.
  • Evaluate the evidence supporting targeted treatment options for salivary gland tumors.